Achieve Life Sciences (NASDAQ:ACHV) Earns Buy Rating from HC Wainwright

Achieve Life Sciences (NASDAQ:ACHV)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research report issued on Wednesday,Benzinga reports. They currently have a $12.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price objective indicates a potential upside of 315.22% from the stock’s current price. HC Wainwright also issued estimates for Achieve Life Sciences’ Q1 2026 earnings at ($0.30) EPS, Q2 2026 earnings at ($0.33) EPS, Q3 2026 earnings at ($0.32) EPS and Q4 2026 earnings at ($0.33) EPS.

A number of other research firms have also recently weighed in on ACHV. Citizens Jmp assumed coverage on Achieve Life Sciences in a research report on Tuesday, November 25th. They set a “market outperform” rating and a $19.00 price objective on the stock. Citigroup initiated coverage on shares of Achieve Life Sciences in a research note on Tuesday, November 25th. They issued an “outperform” rating for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Achieve Life Sciences in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $15.50.

Achieve Life Sciences Trading Up 2.5%

Shares of ACHV stock opened at $2.89 on Wednesday. The company has a debt-to-equity ratio of 0.52, a current ratio of 4.39 and a quick ratio of 5.14. The company has a market cap of $153.83 million, a price-to-earnings ratio of -2.22 and a beta of 1.81. Achieve Life Sciences has a 1 year low of $1.84 and a 1 year high of $6.03. The firm has a fifty day moving average price of $4.38 and a 200-day moving average price of $4.29.

Achieve Life Sciences (NASDAQ:ACHV) last announced its earnings results on Tuesday, March 24th. The biopharmaceutical company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.01). As a group, equities analysts predict that Achieve Life Sciences will post -1.17 earnings per share for the current year.

Hedge Funds Weigh In On Achieve Life Sciences

Several institutional investors have recently bought and sold shares of the stock. Franklin Resources Inc. lifted its stake in Achieve Life Sciences by 81.3% in the 2nd quarter. Franklin Resources Inc. now owns 4,459,014 shares of the biopharmaceutical company’s stock worth $10,077,000 after purchasing an additional 2,000,079 shares in the last quarter. Stonepine Capital Management LLC purchased a new position in shares of Achieve Life Sciences during the second quarter valued at about $753,000. Graham Capital Management L.P. purchased a new position in shares of Achieve Life Sciences during the fourth quarter valued at about $212,000. Dimensional Fund Advisors LP bought a new stake in shares of Achieve Life Sciences in the third quarter worth about $165,000. Finally, ADAR1 Capital Management LLC increased its holdings in shares of Achieve Life Sciences by 10.7% in the third quarter. ADAR1 Capital Management LLC now owns 47,800 shares of the biopharmaceutical company’s stock worth $151,000 after purchasing an additional 4,627 shares during the last quarter. 33.52% of the stock is owned by hedge funds and other institutional investors.

More Achieve Life Sciences News

Here are the key news stories impacting Achieve Life Sciences this week:

• Positive Sentiment: FDA PDUFA set for June 20, 2026 for cytisinicline; company exceeded long‑term safety requirements and secured manufacturing capacity, supporting a potential commercial launch in 1H 2027 if approved. This is the primary near‑term upside catalyst. Achieve Life Sciences: Maintaining ‘Buy’ On Upcoming PDUFA And Expansion Into Vaping Cessation
• Positive Sentiment: Company plans to start the Phase 3 ORCA‑V2 trial for vaping cessation in 1H 2026, expanding the addressable market beyond smoking cessation and adding a second commercialization opportunity. Achieve Life Sciences: Maintaining ‘Buy’ On Upcoming PDUFA And Expansion Into Vaping Cessation
• Positive Sentiment: New publication links cytisinicline’s receptor selectivity to low nausea and favorable tolerability — supportive safety/tolerability data can improve prescribing uptake and payer discussions if approved. Achieve Life Sciences Announces Publication in Nicotine & Tobacco Research
• Positive Sentiment: Unusually large purchases of call options indicate speculative/bullish positioning ahead of the PDUFA and other catalysts, often amplifying upward price moves on positive headlines. Investors Purchase Large Volume of Call Options on Achieve Life Sciences (NASDAQ:ACHV)
• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and maintained a $12 price target (wide upside vs. current levels), and published EPS/quarterly loss forecasts — analyst support lends conviction to the bullish thesis. HC Wainwright buy rating / $12 target (Benzinga)
• Neutral Sentiment: Q4 2025 earnings call summary was published (earnings have been negative historically and management commentary may reiterate runway/milestones) — useful for context but not a new catalytic change versus the regulatory timeline. Achieve Life Sciences, Inc. Q4 2025 Earnings Call Summary

About Achieve Life Sciences

Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.